Uodate: The Ventana's PD-L1 (SP142) Assay was classified as a complementary diagnostic for atezolizumab when the drug was granted accelerated approval from the US Food and Drug Administration in 2016. It has since become a companion diagnostic for the drug in urothelial and other cancers.
To read the full story....
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.